Biotechnology green shoots?
With two life science IPOs earlier this month, and seemingly fewer stories of biotechnology firm liquidations, it seems that the tides are turning — ever so slightly — in the favor of biotechnology. Read more →
Jim Greenwood on Data Exclusivity and Healthcare Innovation
Biotechnology Industry Organization CEO Jim Greenwood appeared on CNBC’s SquawkBox defending the case for data exclusivity protection for novel biologic drugs. The video appears below. Interestingly, he used the Aspirin vs. Epogen comparison from my book, Building Biotechnology, when he was explaining the difference between small molecule and biologic drugs to members of congress.
The impact of the global financial crisis on biotechnology development
My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic hardships, given the direct health and indirect economic benefits of biotechnology research, will governments sustain, increase, or decrease their R&D budgets?
Drug Patent Expirations in August 2009
Courtesy of DrugPatentWatch.com:
Drug Patent Expirations in August 2009
*Drugs may be covered by multiple patents
Read more →
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments